PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) SIMULATIONS GUIDE SELECTION OF THE DOSE FOR ADMINISTRATION OF EFGARTIGIMOD PH20 SUBCUTANEOUSLY IN A PHASE 3 CLINICAL TRIAL IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Ghanima, W. [1 ,2 ,3 ]
McDonald, V. [4 ]
Jain, S. [5 ]
Carpenedo, M. [6 ]
Oliva, E. N. [7 ]
Hultberg, A. [8 ]
Gandini, D. [8 ]
Hofman, E. [8 ]
Van Bragt, T. [8 ]
Parys, W. [8 ]
van Hoorick, B. [8 ]
Godar, M. [8 ]
Rocca, F. [8 ]
Miyakawa, Y. [9 ]
Broome, C. M. [10 ]
机构：
[1] Oslo Univ Hosp, Ostfold Hosp Trust, Dept Med Hematol Oncol & Res, Oslo, Norway
[2] Oslo Univ Hosp, Dept Hematol, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Barts Hlth NHS Trust, London, England
[5] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[6] ASST Osped San Gerardo Monza, Monza, Italy
[7] Grande Osped Metropolitano, Haematol Unit, Reggio Di Calabria, Italy
[8] Argenx Ghent, Ghent, Belgium
[9] Saitama Med Univ Hosp, Saitama, Japan
[10] Georgetown Univ, Washington, DC 20057 USA
来源：
HAEMATOLOGICA | 2022年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P72
引用
收藏
页码：94 / 94
页数：1
相关论文
共 27 条
  • [1] Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
    Ghanima, Waleed
    McDonald, Vickie
    Jain, Shivi
    Carpenedo, Monica
    Oliva, Esther N.
    Hultberg, Anna
    Gandini, Domenica
    Hofman, Erik
    Van Bragt, Tonke
    Parys, Wim
    van Hoorick, Benjamin
    Miyakawa, Yoshitaka
    Broome, Catherine M.
    [J]. BLOOD, 2021, 138
  • [2] Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
    Wittlin, Beatriz
    McDonald, Vickie
    Ghanima, Waleed
    Broome, Catherine
    Hultberg, Anna
    Gandini, Domenica
    Parys, Wim
    Hofman, Erik
    Miyakawa, Yoshitaka
    Jain, Shivi
    Carpenedo, Monica
    Oliva, Esther
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 44 - 44
  • [3] Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis
    Li, George
    Li, Yuebing
    Vu, Tuan
    Korobko, Denis
    Smilowski, Marek
    Liu, Li
    Steeland, Sophie
    Van Hoorick, Benjamin
    Podhorna, Jana
    Casey, Jenna
    Noukens, Jan
    Van Bragt, Tonke
    Utsugisawa, Kimiaki
    Wiendl, Heinz
    De Bleecker, Jan
    Mantegazza, Renato
    Howard, James
    [J]. NEUROLOGY, 2023, 100 (17)
  • [4] Pharmacokinetic/pharmacodynamic (PK/PD) modeling and dose regimen simulations to guide dose selection in phase 2a of an antisense oligonucleotide, targeting human apoB, in hypercholesterolemic subjects
    Yu, Rosie Z.
    Geary, Richard S.
    Bradley, JoAnn
    Chuang, Emil
    Wedel, Mark
    Fuhr, Rainard
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1068 - 1068
  • [5] Pharmacokinetic (PK)/pharmacodynamic (PD) results from a phase Ib study of pegylated hyaluronidase PH20 (PEGPH20) in combination with gemcitabine (Gem) in patients with pancreatic cancer.
    Harris, William Proctor
    Hingorani, Sunil R.
    Beck, Joseph Thaddeus
    Berdov, Boris A.
    Wagner, Stephanie Ann
    Pshevlotsky, Eduard M.
    Tjulandin, Sergei
    Gladkov, Oleg
    Holcombe, Randall F.
    Jiang, Ping
    Maneval, Daniel C.
    Zhu, Joy
    Devoe, Craig E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma
    Ly, Neang
    Zheng, Yanan
    Griffiths, Janet M.
    Merwe, Rene
    Agoram, Balaji
    Parnes, Jane R.
    Roskos, Lorin
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (07): : 901 - 912
  • [7] Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC).
    Jang, H
    Prabhakar, U
    Jiao, Q
    Ford, J
    Miller, BE
    Davis, HM
    Graham, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 189S - 189S
  • [8] Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress
    Newland, Adrian C.
    Liebman, Howard A.
    McDonald, Vickie
    Michel, Marc
    Miyakawa, Yoshitaka
    Parys, Wim
    De Haard, Hans
    Ulrichts, Peter
    Godar, Marie
    De Beuf, Kristof
    Ayguasanosa, Jaume
    Broome, Catherine M.
    Kuter, David J.
    [J]. BLOOD, 2020, 136
  • [9] Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1
    Zhang, Steven
    Amrite, Aniruddha
    Tan, Beesan
    Jamsen, Kris
    Pradhan, Sudeep
    Choy, Steve
    Plotkin, Horacio
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [10] Impact of population pharmacokinetic (PK) modeling, logistic regression and PK/pharmacodynamic (PD) simulation of solabeoron to aid in the dose selection of a phase IIB study in patients with irritable dowel syndrome (IBS).
    Cox, Donna S.
    Boyle, Duane A.
    Foss, Michael J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1101 - 1101
123